These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21750854)

  • 1. [Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study].
    de Juan J; Faraco I; Saiz de la Hoya P; Marco A; Yllobre C; Da Silva A; del Pozo E; Veiras FM;
    Rev Esp Sanid Penit; 2011; 13(2):44-51. PubMed ID: 21750854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
    Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
    BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
    Talal AH; LaFleur J; Hoop R; Pandya P; Martin P; Jacobson I; Han J; Korner EJ
    Aliment Pharmacol Ther; 2013 Feb; 37(4):473-81. PubMed ID: 23289640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
    Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
    Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C virus infection.
    Flamm SL
    JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hepatitis C and HIV in Spanish prisons].
    Soriano V; González-Lahoz J
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):51-2. PubMed ID: 15743572
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
    Préau M; Marcellin F; Spire B; Ravaux I; Dellamonica P; Blanc D; Carrieri MP
    J Clin Gastroenterol; 2008 Jan; 42(1):92-6. PubMed ID: 18097297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting.
    Saiz de la Hoya P; Portilla J; Marco A; García-Guerrero J; Faraco I; Antón J; de Juan J; Pozo E
    Gastroenterol Hepatol; 2014 Oct; 37(8):443-51. PubMed ID: 24786935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
    Cammà C; Petta S
    J Hepatol; 2009 Apr; 50(4):648-51. PubMed ID: 19231012
    [No Abstract]   [Full Text] [Related]  

  • 12. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?
    Souvignet C; Maynard M; Gagnieu MC; Trepo C
    J Hepatol; 2007 Jul; 47(1):1-3. PubMed ID: 17509722
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
    Núñez M; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de Los Santos I; San Joaquín I; Echeverría S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola JM; Romero M; García-Samaniego J; Soriano V;
    AIDS Res Hum Retroviruses; 2007 Aug; 23(8):972-82. PubMed ID: 17725413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
    Bartlett JG
    Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314
    [No Abstract]   [Full Text] [Related]  

  • 19. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
    Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.